Welcome to our dedicated page for Soleno Therapeutics SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soleno Therapeutics filings document the regulatory, financial, governance, and capital-structure disclosures of a Nasdaq-listed biopharmaceutical company commercializing VYKAT XR for hyperphagia associated with Prader-Willi syndrome. Recent Form 8-K reports cover operating results and launch updates, regulatory and marketing-authorization matters for diazoxide choline, material agreements, share-repurchase arrangements, and the company's common stock registration on Nasdaq.
The filing record also includes board-approved bylaw amendments, officer appointments and compensation arrangements, exhibits to earnings releases, and material-event disclosures related to strategic transactions. These documents formalize the company's public reporting around product commercialization, corporate governance, executive compensation, and risk-related business developments.
Soleno Therapeutics (SLNO) reported an equity award and option activity for its Chief Business Officer. On 11/17/2025, the officer acquired 14,286 restricted stock units (RSUs) of common stock at a price of $0, all held directly after the transaction. Each RSU represents the right to receive one share of common stock.
One-half of these RSUs will vest on November 17, 2026, with one third of the remaining units vesting on each one-year anniversary after that, as long as the officer continues as a service provider. The filing also shows an employee stock option covering 64,286 shares of common stock at an exercise price of $47.25 per share, expiring on 11/17/2035. One-fourth of the option shares will vest on November 17, 2026, and one forty-eighth of the shares will vest monthly thereafter, subject to continued service.
Soleno Therapeutics Inc. (SLNO) disclosed a new insider reporting status for its Chief Business Officer through a Form 3 filing. This form identifies the individual as an officer of the company and confirms that the filing is made by a single reporting person. The filing states in the remarks that no securities are beneficially owned, meaning the officer reports holding no Soleno shares or derivative securities as of the event date.
Soleno Therapeutics (SLNO) reported an insider ownership update via a Form 3. The filing identifies the reporting person as an Officer (Chief Development Officer) and states that no securities are beneficially owned as of the event date 11/10/2025. The document serves as an initial statement of ownership under Section 16 and was signed by an attorney-in-fact.
Soleno Therapeutics entered an accelerated share repurchase with Jefferies to repurchase $100.0 million of common stock. The Company prepaid $100.0 million and received an initial delivery of 1,511,553 shares, with any remaining shares expected by the end of its first fiscal quarter of 2026. The final share count will be based on the stock’s volume‑weighted average price during the program, less an agreed discount, with settlement adjustments that could require either party to deliver additional shares or, in Soleno’s case, make a cash payment.
In connection with the ASR, Soleno amended its Oxford Finance loan agreement to permit the repurchase and to modify previously committed capacity. Lenders are no longer obligated to fund the $25.0 million Term C Loans or $25.0 million Term D Loans. After the amendment, the remaining $100.0 million of loans is uncommitted and may be made available only upon mutual agreement.
Soleno Therapeutics (SLNO) reported its first profitable quarter as a commercial company. For Q3 2025, product revenue was $66.0 million, driving operating income of $22.1 million and net income of $26.0 million. Year-to-date, product revenue reached $98.7 million. The company began recognizing sales after the FDA approved VYKAT XR in March 2025 to treat hyperphagia in Prader-Willi syndrome and first prescriptions shipped in April.
Liquidity strengthened significantly: cash and cash equivalents were $246.7 million and marketable securities were $309.4 million at September 30, 2025. In July, Soleno completed an underwritten offering of 2,705,882 shares at $85.00 per share for gross proceeds of $230.0 million (approximately $14.3 million in offering costs). Long-term debt outstanding was $50.0 million under the Oxford facility, with additional tranches available subject to terms. Shares outstanding were 53,710,025 as of October 31, 2025.
Soleno Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended September 30, 2025. The company reported these quarterly results through a press release dated November 4, 2025, which is attached as Exhibit 99.1 to this report and incorporated by reference.
The information is provided under the “Results of Operations and Financial Condition” section of the rules governing current reports and is designated as furnished rather than filed. This means it is not subject to certain liability provisions and is not automatically included in other securities law filings unless specifically referenced.
Soleno Therapeutics (SLNO) disclosed a director equity award. On 10/13/2025, the reporting person was granted 10,046 restricted stock units (RSUs) at $0. Each RSU represents the right to receive one share of common stock.
Vesting: one-third on October 13, 2026 and on each one-year anniversary thereafter, subject to continued service. Beneficial ownership following the grant was 10,046 shares, held directly.
Soleno Therapeutics (SLNO) filed a Form 3 initial statement for a director as of October 13, 2025. The filing reports no securities beneficially owned, with no non-derivative or derivative holdings listed. It was filed by one reporting person and includes an Exhibit 24 Power of Attorney authorizing the signatory.
Soleno Therapeutics (SLNO) expanded its Board and Audit Committee by one seat and appointed Mark W. Hahn as a Class II director, with a term expiring at the 2028 annual meeting. Hahn also joins the Audit Committee.
Hahn brings nearly 30 years of CFO experience, including roles at Verona Pharma (through its first product launch and its approximately $10 billion acquisition by Merck in Oct 2025), Dova Pharmaceuticals (acquired by Sobi for up to $915 million in 2019), and Cempra (led IPO and follow-ons). In connection with his appointment, he received 10,046 RSUs, vesting one-third on Oct 13, 2026 and on each annual anniversary thereafter.
Soleno Therapeutics filed a current report describing a serious adverse event recorded in the FDA’s Adverse Event Reporting System involving a deceased patient who had been treated with VYKAT XR. The treating physician reported, and Soleno agrees, that the case was not related to VYKAT XR.
The patient was a 17-year-old male with Prader-Willi Syndrome and multiple co-morbidities, including lymphedema, superficial thrombophlebitis and severe obesity, and died from an apparent pulmonary embolus. Soleno emphasizes that VYKAT XR was approved after a rigorous clinical program, has an established safety and efficacy profile, and should be used according to its FDA-approved label. The company notes that FAERS reports do not establish causation and cites FDA statements explaining that reported events may stem from underlying disease or other factors.
Soleno explains that Prader-Willi Syndrome is associated with significant co-morbidities and reduced life expectancy, and states that it does not plan to comment on future adverse events, including deaths, unless they are directly related to VYKAT XR use and are unexpected under U.S. Prescribing Information.